ClinicalTrials.gov record
Active, not recruiting Phase 1Phase 2 Interventional

Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors

ClinicalTrials.gov ID: NCT04041310

Public ClinicalTrials.gov record NCT04041310. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 19, 2026, 6:12 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase I/II, Multicenter, Open-Label Study of Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors

Study identification

NCT ID
NCT04041310
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 1, Phase 2
Lead sponsor
Nouscom SRL
Industry
Enrollment
115 participants

Conditions and interventions

Interventions

  • GAd-209-FSP high dose Biological
  • GAd-209-FSP low dose Biological
  • GAd20-209-FSP, RP2D Biological
  • KEYTRUDA® Drug
  • MVA-209-FSP high dose Biological
  • MVA-209-FSP low dose Biological
  • MVA-209-FSP, RP2D Biological

Biological · Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 20, 2019
Primary completion
Oct 29, 2026
Completion
Oct 29, 2026
Last update posted
Feb 12, 2026

2019 – 2026

United States locations

U.S. sites
13
U.S. states
7
U.S. cities
12
Facility City State ZIP Site status
City of Hope Comprehensive Cancer Center Duarte California 91010
City of Hope Comprehensive Cancer Center Irvine California 92618
USC Norris Comprehensive Cancer Center Los Angeles California 90089
USC Norris Comprehensive Cancer Center Newport Beach California 92663
Mt. Sinai Miami Beach Florida 33140
Boca Raton Clinical Research Plantation Florida 33322
Goshen Center for Cancer Care Goshen Indiana 46526
Johns Hopkins University Baltimore Maryland 21287
Washington University School of Medicine, Division of Oncology St Louis Missouri 63110
Roswell Park Comprehensive Cancer Center Buffalo New York 14203
NYU Langone Medical Center New York New York 10016
Weill Cornell Medicine / New York-Presbyterian Hospital New York New York 10021
MD Anderson Cancer Center (MDACC) Houston Texas 77030

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 33 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04041310, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 12, 2026 · Synced May 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04041310 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →